Racial Differences in Radium-223 Treatment Response and Adverse Effects in a Small-Cohort, Pilot, Hypothesis-Generating Observational Study

Affiliations

¹ School of Medicine, University of Mississippi Medical Center, Jackson, MS.
² Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS.
³ Manipal Academy of Higher Education, Manipal, Karnataka, India.
⁴ Department of Radiology, Ochsner Clinic Foundation, New Orleans, LA.

Johnny Yang et al. Ochsner J. 2025 Summer.

. 2025 Summer;25(2):75-76.

doi: 10.31486/toj.25.0023.

¹ School of Medicine, University of Mississippi Medical Center, Jackson, MS.
² Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS.
³ Manipal Academy of Higher Education, Manipal, Karnataka, India.
⁴ Department of Radiology, Ochsner Clinic Foundation, New Orleans, LA.

No abstract available

References

1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi: 10.3322/caac.21763 - DOI - PubMed
1. Iannantuono GM, Chandran E, Floudas CS, et al. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of clinical trials. Cancer Treat Rev. 2023;120:102623. doi: 10.1016/j.ctrv.2023.102623 - DOI - PMC - PubMed
1. Cancer Today. World. World Health Organization: International Agency for Research on Cancer. Accessed April 25, 2025. gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sh...
1. Gillette CM, Yette GA, Cramer SD, Graham LS. Management of advanced prostate cancer in the precision oncology era. Cancers (Basel). 2023;15(9):2552. doi: 10.3390/cancers15092552 - DOI - PMC - PubMed
1. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-223. doi: 10.1056/NEJMoa1213755 - DOI - PubMed